Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Rituximab 56Cyclophosphamide 39fludarabine 23fludarabine phosphate 18Peripheral Blood Stem Cell Transplantation 17Lenalidomide 14Melphalan 13Etoposide 12venetoclax 11Whole-Body Irradiation 11Mycophenolic Acid 11obinutuzumab 10Vincristine 10Prednisone 10Bendamustine Hydrochloride 10Doxorubicin 9Cytarabine 9Cyclosporine 9Bortezomib 9Filgrastim 8pembrolizumab 7Nivolumab 7Gemcitabine 7Busulfan 7acalabrutinib 6Tacrolimus 6Interleukin-2 6Dexamethasone 6Carmustine 6Alemtuzumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Non-Hodgkin × Gene Expression Profiling × Clear all
NCT00691652 2019-11-27

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

OHSU Knight Cancer Institute

Phase 1/2 Terminated
2 enrolled 4 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00601718 2017-05-25

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

University of Washington

Phase 1/2 Completed
29 enrolled 10 charts
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡